drugset / Trial / NCT02701062
AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)
RandomizedParallel-groupOpen-labelOther
Summary
Patients without a documented history of Atrial Fibrillation (AF) and will undergo a valve or Coronary Artery Bypass Graft (CABG) procedure with direct visual access to the Left Atrial Appendage (LAA) will be eligible to participate. Patients enrolled will be randomized 2:1 (2 with AtriClip to 1 without AtriClip. Subjects who develop Post-operative Atrial Fibrillation (POAF) and receive the AtriClip will be followed for 365 days post index procedure.
Timeline
- Start
- 2016-02
- Primary completion
- 2019-04-26
- Completion
- 2019-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Apixaban | Small molecule | — | — |
| Background | Dabigatran | Unknown | — | — |
| Background | Rivaroxaban | Other / unclassified | — | — |
| Background | Warfarin | Small molecule | — | — |